Skip to content

Study · Randomized controlled trial · n = 18 · 2014

6 results

Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.

Breitschaft A, Hu K, Hermosillo Reséndiz K, Darstein C, Golor G

Diabetes research and clinical practice25 Dec 2013Cited by 79 (Europe PMC)

PMID24461109 (opens in a new tab)DOI10.1016/j.diabres.2013.12.011 (opens in a new tab)PepBankPUB-24461109
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy men given pasireotide, co-administered liraglutide reduced the pasireotide-induced rise in plasma glucose AUC after an OGTT by 72% versus pasireotide alone.

    In plain wordsIn healthy men given pasireotide, which raises blood sugar, adding liraglutide cut that rise by 72% compared with pasireotide alone.

    Peptide
    Liraglutide
    Outcome
    DecreasePost-OGTT plasma glucose AUC rise with pasireotide
    Study

    n = 18

    Comparator
    Pasireotide alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.6 mg qd · subcutaneous · 7 daysAs given in this study (human).

    Measurements

    Reduction of pasireotide-induced glucose AUC rise
    72%
    liraglutide
    Glucose AUC increase
    69%
    pasireotide alone

    Source sentences

    Summary
    After 7 days of treatment, plasma glucose AUC post-OGTT increased by 69% with pasireotide alone. The effect was reduced by 13%, 29%, 45% and 72% with co-administration of metformin, nateglinide, vildagliptin and liraglutide, respectively.
    1 context sentence
    Summary · context
    Healthy male volunteers were randomized to pasireotide 600 μg sc bid alone or co-administered with metformin 500 mg po bid, nateglinide 60 mg po tid, vildagliptin 50mg po bid, or liraglutide 0.6 mg sc qd.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy men given pasireotide, co-administered liraglutide attenuated the pasireotide-induced decrease in serum insulin (levels 34% higher) versus pasireotide alone.

    In plain wordsIn healthy men given pasireotide, adding liraglutide reduced the drop in insulin caused by pasireotide, compared with pasireotide alone.

    Peptide
    Liraglutide
    Outcome
    IncreaseSerum insulin decrease with pasireotide, day 7
    Study

    n = 18

    Comparator
    Pasireotide alone
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    0.6 mg qd · subcutaneous · 7 daysAs given in this study (human).

    Measurements

    Serum insulin, higher than pasireotide alone
    34%
    liraglutide

    Source sentences

    Summary
    On day 7, compared with pasireotide alone, the decrease in serum insulin was attenuated with nateglinide, metformin, liraglutide and vildagliptin co-administration (levels were 3%, 6%, 34% and 71% higher, respectively).
    1 context sentence
    Summary · context
    Healthy male volunteers were randomized to pasireotide 600 μg sc bid alone or co-administered with metformin 500 mg po bid, nateglinide 60 mg po tid, vildagliptin 50mg po bid, or liraglutide 0.6 mg sc qd.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy male volunteers, plasma glucose AUC after oral glucose testing increased by 69% after 7 days of pasireotide alone.

    In plain wordsIn healthy male volunteers, glucose exposure after oral glucose testing increased by 69% after 7 days of pasireotide alone.

    Peptide
    Pasireotide
    Outcome
    IncreasePlasma glucose AUC after oral glucose tolerance test
    Study

    n = 18

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    600 μg bid · subcutaneous · 7 daysAs given in this study (human).

    Measurements

    Plasma glucose AUC increase
    69%
    pasireotide alone after 7 days

    Source sentences

    Summary
    After 7 days of treatment, plasma glucose AUC post-OGTT increased by 69% with pasireotide alone.
    4 context sentences
    Summary · context
    This was a 1-week, Phase I, open-label study.
    Summary · context
    Healthy male volunteers were randomized to pasireotide 600 μg sc bid alone or co-administered with metformin 500 mg po bid, nateglinide 60 mg po tid, vildagliptin 50mg po bid, or liraglutide 0.6 mg sc qd.
    Summary · context
    An oral glucose tolerance test (OGTT) was performed on days 1 and 7 to evaluate effects on serum insulin, plasma glucose and glucagon levels.
    Summary · context
    Ninety healthy male volunteers were enrolled (n=18 per arm).
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy male volunteers, serum insulin decreased with pasireotide alone by day 7.

    In plain wordsIn healthy male volunteers, insulin levels decreased with pasireotide alone by day 7.

    Peptide
    Pasireotide
    Outcome
    DecreaseSerum insulin decrease
    Study

    n = 18

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    600 μg bid · subcutaneous · 7 daysAs given in this study (human).

    Source sentences

    Summary
    On day 7, compared with pasireotide alone, the decrease in serum insulin was attenuated with nateglinide, metformin, liraglutide and vildagliptin co-administration (levels were 3%, 6%, 34% and 71% higher, respectively).
    4 context sentences
    Summary · context
    This was a 1-week, Phase I, open-label study.
    Summary · context
    Healthy male volunteers were randomized to pasireotide 600 μg sc bid alone or co-administered with metformin 500 mg po bid, nateglinide 60 mg po tid, vildagliptin 50mg po bid, or liraglutide 0.6 mg sc qd.
    Summary · context
    An oral glucose tolerance test (OGTT) was performed on days 1 and 7 to evaluate effects on serum insulin, plasma glucose and glucagon levels.
    Summary · context
    Ninety healthy male volunteers were enrolled (n=18 per arm).

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 05HumanNot a test of Liraglutide aloneRandomized controlled trialMechanism

    In healthy men given pasireotide with metformin, nateglinide, vildagliptin or liraglutide, minimal changes in plasma glucagon were observed, not reported per arm.

    In plain wordsIn healthy men given pasireotide with one of four diabetes drugs, plasma glucagon changed very little.

    Peptide
    Liraglutide
    Outcome
    No significant changePlasma glucagon
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    Minimal changes in plasma glucagon were observed.
    1 context sentence
    Summary · context
    Healthy male volunteers were randomized to pasireotide 600 μg sc bid alone or co-administered with metformin 500 mg po bid, nateglinide 60 mg po tid, vildagliptin 50mg po bid, or liraglutide 0.6 mg sc qd.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 06HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome

    In healthy men, adverse events across the co-administration arms were consistent with the safety profiles of the drugs used.

    In plain wordsIn healthy men, side effects matched what is already known for each of the drugs used.

    Peptide
    Liraglutide
    Outcome
    No significant changeAdverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Adverse events were consistent with the safety profiles of the drugs used.
    1 context sentence
    Summary · context
    Healthy male volunteers were randomized to pasireotide 600 μg sc bid alone or co-administered with metformin 500 mg po bid, nateglinide 60 mg po tid, vildagliptin 50mg po bid, or liraglutide 0.6 mg sc qd.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 3

    27 Oct 2026, 16:34 UTC

    Study data updated · source update from Europe PMC

  3. Version 2

    12 Oct 2026, 12:10 UTC

    Study results updated

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.